France Refines Early Access System Again

Significant Benefits Seen For Patients With No Other Options

 
• By Ian Schofield

Following last year’s reform of the scheme that allows early access to unapproved or non-reimbursed medicines, the rules are being changed again, including the criteria used to determine whether an “appropriate treatment” is already available.

hand with a rare key, on the background of the
Early access schemes open the door to unapproved medicines • Source: Shutterstock

The French health authorities have refined the criteria for deciding whether an unapproved medicine should be made available under the early-access mechanism, including by making changes to the factors to be taken into account when deciding whether a product is “presumed innovative.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography